期刊
BMJ OPEN
卷 12, 期 11, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2022-068580
关键词
Prostate disease; RADIOTHERAPY; Magnetic resonance imaging
资金
- NIHR Manchester Biomedical Research Centre, UK
- Cancer Research UK (CRUK) Leeds Radiotherapy Research Centre of Excellence [C19942/A28832]
- CRUK Award [95653117/95653118]
- Cancer Research UK Manchester Centre award [CTRQQR-2021\100010]
Radiotherapy is a common treatment for non-metastatic prostate cancer, but a significant number of patients experience recurrence. This study aims to determine the best salvage treatment and evaluate its effectiveness and side effects.
IntroductionRadiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including salvage surgery, brachytherapy (BT), external beam radiotherapy, high-intensity focused ultrasound and cryotherapy. Systematic review shows that high-dose-rate (HDR) BT and stereotactic body radiotherapy (SBRT) have the best outcomes in terms of biochemical control and lowest side effects. The reirradiation options for previously irradiated prostate cancer (RO-PIP) trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage HDR-BT or SBRT and provide prospective data on patient recorded toxicity outcomes that will inform a future phase III trial. Methods and analysisThe primary endpoint of the RO-PIP feasibility study is to evaluate the patient recruitment potential over 2 years to a trial randomising to either SBRT or HDR-BT for patients who develop local recurrence of prostate cancer following previous radiation therapy. The aim is to recruit 60 patients across 3 sites over 2 years and randomise 1:1 to SBRT or HDR-BT. Secondary objectives include recording clinician and patient-reported outcome measures to evaluate treatment-related toxicity. In addition, the study aims to identify potential imaging, genomic and proteomic biomarkers that are predictive of toxicity and outcome based on hypoxia status, a prognostic marker of prostate cancer.Ethics and disseminationThis study has been approved by the Yorkshire and The Humber-Bradford Leeds Research Ethics Committee (Reference: 21/YH/0305, IRAS: 297060, January 2022). The results will be presented in national and international conferences, published in peer-reviewed journals and will be communicated to relevant stakeholders. A plain English report will be shared with the study participants, patients' organisations and media. Trial registration numberISRCTN 12238218 (Amy Ackroyd NIHR CPMS Team).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据